Despite the significance of HER2 amplification/overexpression as a therapeutic target in various tumor types such as breast cancer, gastric cancer and bladder cancer, HER2's importance in ICC has received limited attention due to its infrequent genomic alterations. This evidence concerns the gene ERBB2 and neoplasm.